CDMO Visibility Improves, While Recovery in Medical Devices and Services Still Requires Selective Stock Picking

Overview

The report reviews 2H25 earnings for China's healthcare services and equipment sector and argues that investor focus has shifted from headline growth to backlog depth, order quality, and the credibility of FY26 execution. The CDMO cycle remains intact, while medical devices and medical services show more pronounced stock-specific divergence, with insufficient basis for a broad sector rerating.

Core views

There are two core views: first, CDMO earnings and guidance reinforced that sector momentum remains intact, with order visibility increasingly supported by late-stage development and commercial projects; AI is viewed as an efficiency tool rather than a structural shock to orders, pricing, or backlog quality. Second, recovery in medical devices and medical services still depends on each company's overseas expansion, innovative products, cash flow, and cost control capability, rather than a broad rebound simply driven by easing policy pressure.

Analysis framework

The report breaks down 2H25 earnings, FY26 guidance, orders/backlog, capex, margins, overseas growth, policy pressure, and valuation changes by industry subsegment and key companies, and explains changes in relative risk-reward alongside the rating revisions.

Methodology notes

• Earnings and Guidance2H25 Earnings Review and FY26-28E Forecast Revisions

  Assess growth visibility through company earnings, management guidance, and earnings forecast revisions.

  Goldman Sachs revised FY26-28E earnings forecasts by an average of -2%/0%/0% and adjusted stock ratings based on order conversion, margins, overseas revenue, and cost efficiency.

• Industry MomentumBacklog and Order Quality Analysis

  Use backlog, late-stage projects, and the share of commercial projects to measure medium-term CDMO visibility.

  Backlog growth at WuXi AppTec, WuXi Biologics, and WuXi XDC indicates resilient demand, with investor focus shifting to order conversion and margin delivery.

• Valuation methodsTarget Price and Relative Risk-Reward Assessment

  Assess target prices and ratings through DCF, exit P/E, discount rates, and consensus gaps.

  AK Medical's target price is based on a discounted 2028E exit P/E, MicroTech uses a risk-adjusted DCF, and Topchoice's lower target price reflects slower revenue recovery and more conservative long-term growth assumptions.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec

  Preferred name

  Strengths

  Strong backlog conversion, lower FX risk, and sustained TIDES momentum improve FY26 growth visibility.

  Weaknesses

  Order conversion and margin delivery still need continued validation.

  Comparison

  Superior within CDMO to companies with weaker growth visibility or less clear overseas capacity ramp-up.

  Risks

  FX volatility, geopolitics, order delays, and lower-than-expected capacity utilization.

• Asymchem

  Preferred name

  Strengths

  Backlog-driven growth, with emerging services such as peptides and ADCs boosting medium-term confidence.

  Weaknesses

  Higher capex requires delivery on utilization and order conversion.

  Comparison

  Contributions from emerging services provide clearer incremental growth drivers within CDMO.

  Risks

  Slower-than-expected ramp-up in new businesses and lower-than-expected returns on cost investment.

• AK Medical

  Upgraded to Buy

  Strengths

  Improved profit quality in 2H25, gross margin of about 62%, stronger contribution from overseas revenue and digital orthopedics, and a clearer roadmap for surgical robot deployment.

  Weaknesses

  Industry volume recovery remains gradual, and near-term robot revenue contribution is limited.

  Comparison

  Compared with traditional device stocks with unclear recovery, AK Medical has clearer improvement in margins and strategic optionality.

  Risks

  Slow recovery in non-VBP procedure volume, cost or expense pressure, delayed monetization of robots, and policy and competitive risks.

• MicroTech Medical

  Upgraded from Sell to Neutral

  Strengths

  FY26 revenue growth guidance of no less than 35%, CGM growth above 50%, competitive pressure lower than previously feared, and initial progress in overseas markets.

  Weaknesses

  Domestic CGM competition remains intense, and the pace of overseas commercialization and litigation impact still need to be monitored.

  Comparison

  Risk-reward is more balanced than before, but upside remains unremarkable relative to the covered universe.

  Risks

  Intensifying competition in CGMS and insulin pumps, overseas execution risk, capacity ramp-up, regulatory approval, and product development risks.

• Topchoice Medical

  Downgraded from Neutral to Sell

  Strengths

  Fundamentals are relatively stable, and management still expects a summer rebound.

  Weaknesses

  Dental implant volume recovery is below expectations, the low-price strategy has yet to clearly drive volume growth, and the consumer environment remains under pressure.

  Comparison

  Less attractive relative to names with clearer demand catalysts or margin drivers.

  Risks

  Revenue recovery continues to lag expectations, the low-price strategy compresses margins, and consumer demand remains weak.

• Shandong Weigao

  Downgraded to Neutral

  Strengths

  Valuation and shareholder returns provide some downside support.

  Weaknesses

  VBP-related margin pressure remains, with limited near-term growth.

  Comparison

  Weaker upside elasticity than device stocks with overseas expansion or innovative product catalysts.

  Risks

  Slow post-VBP margin recovery, revenue growth below 5-8% guidance, and weaker-than-expected product mix improvement.

Key data

• CDMO BacklogWuXi AppTec 2025 backlog US$8,169mn; WuXi Bio US$4,530mn; WuXi XDC US$1,490mnThe chart shows that backlog at all three companies continued to grow versus 2024.
• CDMO Capital ExpenditureWuXi Biologics FY26 capex about Rmb7.1bn; WuXi XDC about Rmb3.1bn; Asymchem about Rmb2.1bnCapex is more closely tied to visible demand, overseas capacity, ADC, peptides, and commercial projects.
• AK Medical Rating and ValuationUpgraded to Buy; 12-month target price HK$8.40; price HK$6.89; upside 21.9%The main reasons are improved margins, overseas revenue growth, and a clearer surgical robot roadmap.
• MicroTech Medical Rating and ValuationUpgraded from Sell to Neutral; 12-month target price HK$8.90; price HK$7.97; upside about 11.7%FY26 revenue growth guidance is no less than 35%, with CGM growth guidance above 50%.
• Topchoice Medical Rating and ValuationDowngraded from Neutral to Sell; 12-month target price Rmb38.10; price Rmb41.35The low-price strategy has yet to bring clear revenue reacceleration, and revenue growth is forecast at 9%, below management's 30% guidance.
• Overseas GrowthMicroTech overseas growth 227% YoY, Angelalign overseas growth 103%, AK Medical overseas growth 20%Overseas expansion has become a key growth driver for some medical device companies.
• Exposure to Reimbursed RevenueHygeia and Gushengtang about 40%, Aier about 25%, Jinxin Fertility below 20%, Topchoice about 10%Reimbursement exposure affects the revenue and earnings resilience of medical service companies under DRG/DIP pressure.

Impact & implications

For portfolios, the report suggests avoiding treating China's healthcare services and equipment sector as a homogeneous recovery trade, and instead selecting names based on CDMO order visibility, medical device globalization, innovative products, margin recovery, and cash flow returns. CDMO remains the relatively more attractive direction, while the services sector and some traditional consumables need more evidence of revenue reacceleration and margin improvement.

Risks

• CDMO order conversion, capacity utilization, or margin delivery may fall short of expectations.
• Geopolitics, FX volatility, and overseas capacity ramp-up may create uncertainty.
• Medical device VBP, DRG/DIP, anti-corruption, or procurement reimbursement policies may tighten again.
• Recovery in medical service demand and consumption may be slower than expected, and pricing strategies may fail to effectively drive volume growth.
• Competition in CGM, surgical robots, and high-end medical devices may intensify, putting pressure on ASP and gross margins.
• Risks related to overseas commercialization, channel building, regulatory approvals, and IP litigation.

What to watch

• FY26 order growth, backlog conversion rate, and the share of late-stage/commercial projects at CDMO companies.
• The match between capex and utilization at WuXi AppTec, Asymchem, WuXi Biologics, and WuXi XDC.
• Updates on AK Medical's surgical robot installations, robot-assisted surgery volumes, service fee reform, and tender data.
• MicroTech CGM overseas reimbursement coverage, European expansion, ASP changes, and patent litigation progress.
• Whether Topchoice's low-price strategy leads to reacceleration in dental implant volume and revenue.
• Execution by Hygeia, Jinxin Fertility, and Gushengtang in cash flow, leverage, buybacks, and expansion.